Home
BDRX
BDRX News

Latest Biodexa Pharmaceuticals plc (BDRX) News on October 8, 2025

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

GlobeNewswire

2 days ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

MT Newswires

5 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 3.3% for Week

MT Newswires

6 days ago

European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading

MT Newswires

a month ago

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

ACCESS Newswire

a month ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Results of Annual General Meeting

GlobeNewswire

3 months ago

Results of Annual General Meeting

MT Newswires

3 months ago

European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

GlobeNewswire

3 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

MT Newswires

3 months ago

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

GlobeNewswire

3 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

ACCESS Newswire

4 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

GlobeNewswire

4 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

GlobeNewswire

4 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Biodexa Pharmaceuticals sees cash runway into 1Q26

TipRanks

4 months ago

Biodexa Pharmaceuticals sees cash runway into 1Q26

Shareholder Update

GlobeNewswire

4 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

GlobeNewswire

5 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

GlobeNewswire

5 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

GlobeNewswire

5 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Result of General Meeting

GlobeNewswire

5 months ago

Result of General Meeting

Notice of General Meeting

GlobeNewswire

6 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

GlobeNewswire

6 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

ACCESS Newswire

7 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

GlobeNewswire

7 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

GlobeNewswire

7 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

GlobeNewswire

7 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

GlobeNewswire

8 months ago

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

GlobeNewswire

8 months ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

ACCESS Newswire

8 months ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

GlobeNewswire

8 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

GlobeNewswire

9 months ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Result of General Meeting

GlobeNewswire

a year ago

Result of General Meeting

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

ACCESSWIRE

a year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

GlobeNewswire

a year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Notice of General Meeting

GlobeNewswire

a year ago

Notice of General Meeting

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

ACCESSWIRE

a year ago

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

GlobeNewswire

a year ago

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

GlobeNewswire

a year ago

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Interim results for the six months ended June 30, 2024

GlobeNewswire

a year ago

Interim results for the six months ended June 30, 2024

ADR Ratio Change

GlobeNewswire

a year ago

ADR Ratio Change

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

GlobeNewswire

a year ago

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

Receipt of Nasdaq Delisting Determination - Plans to Appeal

GlobeNewswire

a year ago

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire

a year ago

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire

a year ago

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

GlobeNewswire

a year ago

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

ACCESSWIRE

a year ago

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

GlobeNewswire

a year ago

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

GlobeNewswire

a year ago

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

GlobeNewswire

a year ago

Results of Annual General Meeting

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

GlobeNewswire

a year ago

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

CNW Group

a year ago

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

ACCESSWIRE

a year ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Business Insider

a year ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

GlobeNewswire

a year ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Motley Fool

a year ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Unifor members vote to strike at Manitoba Hydro

CNW Group

a year ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly

AFP

a year ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Business Insider

a year ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer

ACCESSWIRE

a year ago

Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer

GlobeNewswire

a year ago

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

GlobeNewswire

a year ago

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Posting of Annual Report & Notice of AGM - Total Voting Rights

GlobeNewswire

a year ago

Posting of Annual Report & Notice of AGM - Total Voting Rights

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

ACCESSWIRE

a year ago

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting

GlobeNewswire

a year ago

Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

GlobeNewswire

a year ago

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

Preliminary Results for the Year Ended 31 December 2023

GlobeNewswire

a year ago

Preliminary Results for the Year Ended 31 December 2023

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

ACCESSWIRE

2 years ago

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

ACCESSWIRE

2 years ago

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

GlobeNewswire

2 years ago

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

GlobeNewswire

2 years ago

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone

GlobeNewswire

2 years ago

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

GlobeNewswire

2 years ago

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

PR Newswire

2 years ago

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

LENSAR Decline Means Insider Profits Down To US$42k

Simply Wall St.

2 years ago

LENSAR Decline Means Insider Profits Down To US$42k

PR Newswire

2 years ago

/DISREGARD RELEASE: Visionary Education Technology Holdings Group Inc./

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

GlobeNewswire

2 years ago

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

Business Wire

2 years ago

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

ACCESSWIRE

2 years ago

Vision Marine Technologies Inc. Announces Close of $3.0 Million Private Placement of Convertible Preferred Shares and Warrants with Investissement Québec

Visionary Education Group Established a MOU with Algoma University

PR Newswire

2 years ago

Visionary Education Group Established a MOU with Algoma University

Vision Marine Technologies Inc. (VMAR) Reports Q1 Loss, Misses Revenue Estimates

Zacks

2 years ago

Vision Marine Technologies Inc. (VMAR) Reports Q1 Loss, Misses Revenue Estimates

Hepion Pharmaceuticals to Present at NASH-TAG 2024

GlobeNewswire

2 years ago

Hepion Pharmaceuticals to Present at NASH-TAG 2024

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

GlobeNewswire

2 years ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Edgio Promotes Todd Hinders to Chief Executive Officer

Business Wire

2 years ago

Edgio Promotes Todd Hinders to Chief Executive Officer

Biodexa Appoints Ann Merchant to the Board of Directors

GlobeNewswire

2 years ago

Biodexa Appoints Ann Merchant to the Board of Directors

12 Most Profitable Pot Stocks Now

Insider Monkey

2 years ago

12 Most Profitable Pot Stocks Now

La Rosa Acquires Fifth Real Estate Brokerage Franchisee with Revenue of $3.6 Million and Positive Net Income in 2022

GlobeNewswire

2 years ago

La Rosa Acquires Fifth Real Estate Brokerage Franchisee with Revenue of $3.6 Million and Positive Net Income in 2022

11 Popular Penny Stocks on Robinhood

Insider Monkey

2 years ago

11 Popular Penny Stocks on Robinhood

GlobeNewswire

2 years ago

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

GlobeNewswire

2 years ago

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

CORRECTING and REPLACING Edgio Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

2 years ago

CORRECTING and REPLACING Edgio Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Safeguard Scientifics’ Board of Directors Declares Contingent Cash Dividend of $0.35 Per Share

GlobeNewswire

2 years ago

Safeguard Scientifics’ Board of Directors Declares Contingent Cash Dividend of $0.35 Per Share

GlobeNewswire

2 years ago

Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes

SteraMist Welcomes Sterile Grow as U.S. Distributor for Food Safety and Cannabis

GlobeNewswire

2 years ago

SteraMist Welcomes Sterile Grow as U.S. Distributor for Food Safety and Cannabis

Associated Press Finance

2 years ago

Ituran: Q3 Earnings Snapshot

ITURAN PRESENTS THIRD QUARTER 2023 RESULTS

PR Newswire

2 years ago

ITURAN PRESENTS THIRD QUARTER 2023 RESULTS

PR Newswire

2 years ago

Jianpu Technology Inc. Reports Third Quarter 2023 Unaudited Financial Results

Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon

Simply Wall St.

2 years ago

Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon

Insider Spends US$59k Buying More Shares In Crown Crafts

Simply Wall St.

2 years ago

Insider Spends US$59k Buying More Shares In Crown Crafts

InvestorPlace

2 years ago

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

GlobeNewswire

2 years ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

PR Newswire

2 years ago

Jianpu Technology Inc. to Report Third Quarter 2023 Financial Results on Friday, November 24, 2023

Share on Social Networks: